Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 164]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Trevena, Inc. - Market capitalization
Trevena, Inc.
TRVN

$1.47 M
Marketcap
$1.70
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

marketcap